Alivus Life Sciences Holds 15th AGM on Sep 8, 2026; Approves Dividend & Director Re-appointment
Alivus Life Sciences Limited held its 15th AGM on September 8, 2026. The company declared a final dividend of ₹5 per equity share for FY26 and re-appointed Mr. Hiren Patel as a Director. The audited financial statements for FY26 were approved, and the remuneration of the Cost Auditor for FY27 was ratified.
The declaration of dividend and re-appointment of a director are significant events for shareholders, impacting their returns and corporate governance.
The AGM proceedings were positive, with the approval of financial statements, dividend declaration, and re-appointment of a director. Management commentary also reflected confidence in future growth.
Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) held its 15th Annual General Meeting (AGM) on Tuesday, September 8, 2026. The meeting commenced at 3:00 p.m. IST and concluded at 4:40 p.m., conducted through Video Conferencing (VC)/Other Audio Visual Means (OAVM) with webcast facility provided to members.
During the AGM, several key resolutions were put to vote and passed. These included the adoption of the Audited Financial Statements for the financial year ended March 31, 2026, the declaration of a final dividend of ₹5 per equity share for the same financial year, and the re-appointment of Mr. Hiren Patel as a Director. Additionally, the remuneration of the Cost Auditor for the financial year ending March 31, 2027, was ratified.
The Chairman, Mr. Hiren Patel, and Managing Director & CEO, Dr. Yasir Rawjee, addressed the shareholders, highlighting the company's strong financial performance, revenue growth, record profitability, business diversification, and future growth strategy. They emphasized continued investments in manufacturing, R&D, and technology, along with a commitment to sustainability initiatives and long-term value creation for shareholders. The Scrutinizer's Report was received on September 8, 2026, confirming that all resolutions were passed with the requisite majority.
What to do with a filing like this
Alivus Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alivus Life Sciences Limited. Read the original for the full detail.